Andrew Sherwood

Andrew Sherwood

Auto-generated profile, based on publicly available information

Andrew Sherwood

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
PWPeter Willeit
Peter Willeit
LTLena Tschiderer
Lena Tschiderer
EAElias Allara
Elias Allara
KRKathrin Reuber
Kathrin Reuber
LSLisa Seekircher
Lisa Seekircher
FGFor the PROG-IMT and the Proof-ATHERO Study Groups
For the PROG-IMT and the Proof-ATHERO Study Groups
Background: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk. Methods: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach. Results: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 μm/y reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87–0.94), with an additional relative risk for CVD of 0.92 (0.87–0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 μm/y would yield relative risks of 0.84 (0.75–0.93), 0.76 (0.67–0.85), 0.69 (0.59–0.79), or 0.63 (0.52–0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients. Conclusions: The extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials.

26 February 2007 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
ASAndrew Sherwood
Andrew Sherwood
JBJames A. Blumenthal
James A. Blumenthal
RTRanak Trivedi
Ranak Trivedi
KJKristy S. Johnson
Kristy S. Johnson
COChristopher M. O’connor
Christopher M. O’connor
AHAlan L. Hinderliter
Alan L. Hinderliter
Heart failure (HF) is characterized by markedly compromised cardiac function, high rate of complications, and decreased life expectancy.1 Impaired cardiac function and neurohumoral activation are the defining characteristics of HF that contribute to clinical deterioration, and the focus of interventions has generally been on improving circulatory function and on blocking the renin-angiotensin and sympathetic nervous systems.2 Depression is widely considered a significant psychosocial risk factor in patients with coronary heart disease.3 Depression is associated with a substantially increased risk of developing HF in individuals at risk4 and has been associated with adverse outcomes in patients with established HF. In a study by Jiang et al5 of 374 hospitalized patients with HF who underwent screening for depression, those with major depression were approximately twice as likely to die or be rehospitalized within 1 year. Similarly, Vaccarino et al6 reported that severity of depressive symptoms was related to death or functional decline at 6-month follow-up in 391 hospitalized patients with HF. Murberg and Furze7 recently reported findings of 6-year follow-up in 119 patients with HF in whom symptoms of depression at baseline were predictive of death. Because depression in patients with HF is related to disease severity, however, there remains uncertainty about the extent to which depression, independent of HF severity, is related to adverse clinical outcomes.8 In the last few years, B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), which are released from the cardiac ventricles and have vasodilator and diuretic effects, have emerged as standard diagnostic and prognostic markers of HF.9,10 In the present prospective study of 204 outpatients with HF, we used NT-proBNP to adjust for HF severity in evaluating whether symptoms of depression were related to death and hospitalizations during 3 years of follow-up.

1 February 2002 in American Journal of Hypertension
Verified
Journal Article
Closed access
ASA. Sherwood
A. Sherwood
PSP. R. Steffen
P. R. Steffen
JBJ. A. Blumenthal
J. A. Blumenthal
CKC. Kuhn
C. Kuhn
AHA. L. Hinderliter
A. L. Hinderliter
There is a marked diurnal variation in blood pressure (BP), with BP dipping to its lowest levels during nighttime sleep. A day-night dip in systolic BP (SBP) of <10% has been used to characterize individuals as nondippers, and is associated with an increased risk for cardiovascular disease. The present study examined the contribution of the sympathetic nervous system (SNS) to BP dipping in a biracial sample of 172 men and women aged 25 to 45 years. Assessments included 24-h ambulatory BP monitoring and both waking and sleeping urinary catecholamines. In addition, cardiovascular alpha- and beta-adrenergic receptor (AR) responsiveness was determined by the doses of isoproterenol and phenylephrine required to attain an increase in heart rate of 25 points (CD25) and BP (PD25), respectively. Compared with dippers (n = 116), nondippers (n = 56) were more likely to be African American and to have a family history of hypertension as well as a higher body mass index (BMI). The nighttime fall in both norepinephrine (NE) and epinephrine (EPI) excretion rates was reduced in nondippers compared with dippers (NE dip 9.3 v 13.1 microg/mg; EPI dip 2.7 v 4.0 microg/mg; both P < .05). Nondippers also were characterized by heightened alpha1-AR responsiveness compared with dippers (PD25 = 252 v 321 microg, P < .05). These data suggest that the SNS may contribute to individual differences in nighttime BP dipping, and appears to account in part for blunted BP dipping in African Americans.

1 August 2005 in JACC
Verified
Journal Article
Closed access
ASAndrew Sherwood
Andrew Sherwood
AHAlan L. Hinderliter
Alan L. Hinderliter
LWLana L. Watkins
Lana L. Watkins
RWRobert A. Waugh
Robert A. Waugh
JBJames A. Blumenthal
James A. Blumenthal

1 September 2003 in Psychosomatic Medicine
Verified
Journal Article
Closed access
PSPatrick R. Steffen
Patrick R. Steffen
MMMaya McNeilly
Maya McNeilly
NANorman Anderson
Norman Anderson
ASAndrew Sherwood
Andrew Sherwood
Hypertension is more prevalent in African Americans compared with Americans of European descent. Preliminary evidence indicates that perceived racism may play a role in elevated blood pressure in African Americans. The present study examined whether perceived racism was associated with higher ambulatory blood pressure measured during daily life. A potential contributing role for anger inhibition was also evaluated. Twenty-four–hour ABP was obtained from 69 African American men and women with normal or mildly elevated blood pressure. ABP was averaged over waking and sleep periods, and clinic BP was also assessed. Perceived racism and anger expression were measured using self-report questionnaires. Greater perceived racism was related to higher ABP during waking hours for SBP (p < .01) and DBP (p < .05). Perceived racism was positively correlated with anger inhibition (r = .29, p < .05) but was not related to outwardly expressed anger (r = .01, NS). Anger inhibition was related to higher sleep DBP (p = .05) and a smaller drop in DBP from day to night (p < .05). Anger inhibition did not account for the relationship between perceived racism and blood pressure. Perceived racism and anger inhibition are independently related to higher ABP. Both may contribute to the incidence of hypertension and hypertensive-related diseases observed in African Americans.

1 January 2011 in JACC
Verified
Journal Article
Closed access
ASAndrew Sherwood
Andrew Sherwood
JBJames A. Blumenthal
James A. Blumenthal
AHAlan L. Hinderliter
Alan L. Hinderliter
GKGary G. Koch
Gary G. Koch
KAKirkwood F. Adams
Kirkwood F. Adams
COChristopher M. O'COnnor
Christopher M. O'COnnor